1. The potential for QT prolongation and proarrhythmia by non-arrhythmic drugs: clinical and regulatory implications: report on a policy conference of the European Society of Cardiology;Haverkamp;Eur Heart J,2000
2. Cardiac repolarization: current knowledge, critical gaps and new approaches to drug development and patient management;Anderson;Am Heart J,2002
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. Geneva, Switzerland: International Conference on Harmonisation, 2005.
4. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Geneva, Switzerland: International Conference on Harmonisation, 2005.
5. Drug-induced prolongation of the QT interval;Roden;N Eng J Med,2004